Ambien IR

Ambien IR (immediate-release) is a sedative-hypnotic medication containing zolpidem tartrate, a non-benzodiazepine imidazopyridine. It functions as a positive allosteric modulator of the gamma-aminobutyric acid A (GABAA) receptor, specifically targeting the alpha-1 subunit (also known as the BZ1 or omega-1 receptor), which is primarily responsible for sedative effects. Developed by Synthelabo in collaboration with Searle and receiving FDA approval in 1992, Ambien IR is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset. The medication is designed for rapid absorption, reaching peak plasma concentrations approximately 0.9 hours after administration. It is available in 5 mg and 10 mg oral tablets and is classified as a Schedule IV controlled substance.

Brand names

Ambien

Other names

zolpidem tartratezolpidem